PureTech Health plc - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
PRTCY Over the counter 3840 www.puretechhealth.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PureTech Health plc

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - Jul 13th, 2026 12:00 am
Celea Therapeutics secures $180m for Phase III SURPASS-IPF trial - Jul 3rd, 2026 5:06 am
A PureTech startup banks $180M for a new IPF drug - Jul 2nd, 2026 5:04 am
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) - Jul 2nd, 2026 12:01 am
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) - Jul 2nd, 2026 12:01 am
PureTech Health: Results of Annual General Meeting - Jun 10th, 2026 11:14 am
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Jun 9th, 2026 12:00 am